Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MITEK SURGICAL STOCK JUMPS 2-1/2 IN JULY TO 26-1/2

This article was originally published in The Gray Sheet

Executive Summary

MITEK SURGICAL STOCK JUMPS 2-1/2 IN JULY TO 26-1/2, a 10.4% gain, on strong second-quarter sales and earnings. Mitek announced July 23 that sales soared 60.8% to $5.2 mil. and earnings gained 59.3% to $893,483 for the three-month period ended June 30 ("The Gray Sheet" Aug. 2, p. 18). The Norwood, Massachusetts firm reported that sales of anchor products for the reattachment of soft tissue to bone grew by 77% during the first six months of 1993. Mitek was one of only four stocks on "The Gray Sheet" monthly Index of over-the-counter issues to advance by 10% or more in July. Overall, 26 issues declined, 14 advanced, and one, St. Jude, was flat for the month. Smaller devices firms were particularly hard hit: 11 of the 14 Index stocks valued at less than $100 mil. declined for the month. However, gains by some of the more heavily weighted issues held the composite Index loss for the month to 1.6%. Scimed, for example, jumped 7.7% or 4-3/4 to 66-3/4 in July, making it the leading point gainer for the period. On July 22, Scimed said it would launch a new percutaneous transluminal coronary angioplasty guidewire system "within the next few months" ("The Gray Sheet" July 26, In Brief). A week later, the company said it would establish a direct sales force of five-to-15 reps in Japan by the end of the year ("The Gray Sheet" Aug. 2, In Brief). At 66-3/4, Scimed is carrying a price-to- earnings ratio of 18. Among other cardiovascular firms followed by the Index, Cordis moved up 1-7/8 or 5.9% to 33-7/8 in July. During the month, FDA approved its Sleek Long angioplasty catheters with 3 cm and 4 cm balloons and the Predator dilatation catheter ("The Gray Sheet" Aug. 2, In Brief). Datascope, which recently divested its angioplasty division ("The Gray Sheet" June 14, p. 11), was off 3/4, or 5%, to 14-1/4 for the month. Elyria, Ohio-based home care and mobility products firm Invacare gained 2-1/4 to 25-1/4 last month, a 9.8% advance. The firm was among those reporting strong financial results during the month ("The Gray Sheet" Aug. 2, p. 18). The company also announced its most recent acquisition, GSI, Inc., on July 13 ("The Gray Sheet" July 19, p. 23). Electrotherapeutic device firm Empi skidded 7-3/8, or 23.1%, to 24-5/8 in July. Among the top O-T-C Index performers in the first half of 1993, the stock underwent a strong correction following a July 12 article in Barron's which questioned the efficacy of transcutaneous electrical nerve stimulation (TENS) devices. Federal budgetary concerns may also be putting pressure on the TENS field in general: House/Senate budget reconciliation legislation, for example, calls for further reductions in Medicare TENS payments. Target Therapeutics dipped 1/2 or 2.3% to 21-3/4 in July. The Fremont, California company reported during the month "that it is in the process of formulating a response to questions" raised by FDA regarding its Guglielmi Detachable Coil. A 510(k) for the device, designed to treat cerebral aneurysms, was submitted last November ("The Gray Sheet" Nov. 2, 1992, p. 9). "The company believes that it can respond to these questions using existing data supplemented with results from minor additional in vitro laboratory tests," according to Target.

You may also be interested in...



Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel